Application of NADH and NMN in preparation of drug or health caring product for Parkinson's disease
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology for Parkinson's disease and health care products, which is applied in the application field of preparing Parkinson's disease drugs or health care products, can solve problems such as high cost and need to be improved, and achieve the effects of easy and stable efficacy, high safety and obvious efficacy.
Inactive Publication Date: 2015-07-08
HOBOOMLIFE BIO TECH SHENZHEN CO LTD
View PDF4 Cites 12 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
[0005] In view of the above-mentioned deficiencies in the prior art, the purpose of the present invention is to provide the application of NADH and NMN in the preparation of Parkinson's disease medicine or health care product, aiming to solve the problem of high cost and effect of existing Parkinson's disease medicine or health care product. question
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0025] Example 1: Application of NADH and NMN in the preparation of Parkinson's disease medicine or health products
[0026] Various dosage forms are prepared by using conventional methods in the field of medicine and health care products, and pharmaceutically acceptable auxiliary materials. When used for oral administration, it can be prepared into conventional solid preparations such as tablets, powders or capsules, etc.; when used for injection, it can be prepared as injection solution.
[0027] (1) Weigh: 10 grams of β-NADH and 10 grams of β-NMN;
[0028] 40 grams of D-mannitol; 20 grams of microcrystalline cellulose;
[0029] (2) Mix and compress: add 0.5 g of magnesium stearate, mix and compress;
[0030] (3) Coating: Use 2.5 grams of isolation coating and 8 grams of enteric coating solution;
[0031] (4): Tablet packaging is made into a pharmaceutical composition.
Embodiment 2
[0032] Example 2: Clinical data of the pharmaceutical composition containing β-NADH and β-NMN in the treatment of Parkinson's disease
[0033] Parkinson's disease diagnostic criteria
[0034] 1.1 Material: enteric-coated tablet of pharmaceutical composition containing β-NADH and β-NMN,
[0035] 1.2 Admitted patients and clinical manifestations: a total of 100 cases of Parkinson's disease, patients over 60 years old. Main manifestations: tremor, bradykinesia, abnormal posture and gait. Parkinson's syndrome caused by encephalitis, cerebrovascular disease, poisoning, and trauma was excluded, and it was distinguished from hysterical and tonic tremor.
[0036] 1.3 Administration method: The tablet of the above-mentioned Example 1 was selected, dissolved in water and administered to the patient, 2 tablets each time, taken on an empty stomach every morning, 30 days as a course of treatment, and 3 courses of treatment were taken continuously.
[0037] Efficacy Evaluation Criteria ...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Login to view more
Abstract
The invention discloses an application of NADH and NMN in preparation of a drug or a health caring product for Parkinson's disease, namely, [beta]-NADH and [beta]-NMN are applied for preparing the drug or the health caring product for the Parkinson's disease, wherein the [beta]-NADH and [beta]-NMN are prepared through enzyme catalysis. The invention provides the new drug or health caring product, which is prepared from the [beta]-NADH and [beta]-NMN which is prepared in an in-vitro enzyme catalysis manner, has cost advantage and is high in purity. The drug or health caring product is used for treating the Parkinson's disease. The [beta]-NADH and the [beta]-NMN, as active components, are used for preparing the drug or the health caring product for the Parkinson's disease, wherein the particular dosage can be decided according to the severity degree of the diseases, drug application approach and relative factors. The [beta]-NADH and the [beta]-NMN themselves exist in body cells, so that the [beta]-NADH and the [beta]-NMN are high in safety as the drug or the health caring product. In addition, the NMN is a monomer molecule so that the drug or the health is significant in function and is easy to stabilize.
Description
technical field [0001] The invention relates to the field of medicine and health care products, in particular to the application of NADH and NMN in the preparation of Parkinson's disease medicine or health care products. Background technique [0002] Parkinson's disease (PD), also known as parkinsonism, is one of the most common neurodegenerative diseases. Epidemiology shows that the prevalence rate is 15-328 / 100,000 population, about 1% of people >65 years old; the incidence rate is 10-21 / 100,000 population / year. [0003] In the prior art, Parkinson’s disease drugs or health care products include compound levodopa preparations, dopamine receptor agonists, monoamine oxidase inhibitors, anticholinergic agents, and amantadine; some patients may consider neuron nucleus damage surgery or Deep brain stimulation surgery, but the cost of these existing drugs or health care products is too high for patients to bear the high price, and the effect needs to be improved. [0004] T...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more 
Login to view more